Several members of the SGLT-2 inhibitors class of medications have shown robust treatment effects in patients with type 2 diabetes mellitus as well as heart failure and chronic kidney disease and are therefore unequivocally recommended by clinical practice guidelines [79–81] for the treatment in aforementioned indications. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.